Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/122858
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vinaixa, Maria | - |
dc.contributor.author | Rodríguez, Miguel Angel | - |
dc.contributor.author | Samino Gené, Sara | - |
dc.contributor.author | Díaz, Marta | - |
dc.contributor.author | Ribas i Beltran, Antoni, 1946- | - |
dc.contributor.author | Mallol, Roger | - |
dc.contributor.author | Bladé, Cinta | - |
dc.contributor.author | Ibáñez Toda, Lourdes | - |
dc.contributor.author | Correig, Xavier | - |
dc.contributor.author | Yanes, Oscar | - |
dc.date.accessioned | 2018-06-08T10:11:18Z | - |
dc.date.available | 2018-06-08T10:11:18Z | - |
dc.date.issued | 2011-12-16 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2445/122858 | - |
dc.description.abstract | Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity, low-grade inflammation and increased cardiovascular disease risks. Recently, a new polytherapy consisting of low-dose flutamide, metformin and pioglitazone in combination with an estro-progestagen resulted in the regulation of endocrine clinical markers in young and non-obese PCOS women. However, the metabolic processes involved in this phenotypic amelioration remain unidentified. In this work, we used NMR and MS-based untargeted metabolomics to study serum samples of young non-obese PCOS women prior to and at the end of a 30 months polytherapy receiving low-dose flutamide, metformin and pioglitazone in combination with an estro-progestagen. Our results reveal that the treatment decreased the levels of oxidized LDL particles in serum, as well as downstream metabolic oxidation products of LDL particles such as 9- and 13-HODE, azelaic acid and glutaric acid. In contrast, the radiuses of small dense LDL and large HDL particles were substantially increased after the treatment. Clinical and endocrine-metabolic markers were also monitored, showing that the level of HDL cholesterol was increased after the treatment, whereas the level of androgens and the carotid intima-media thickness were reduced. Significantly, the abundance of azelaic acid and the carotid intima-media thickness resulted in a high degree of correlation. Altogether, our results reveal that this new polytherapy markedly reverts the oxidant status of untreated PCOS women, and potentially improves the pro-atherosclerosis condition in these patients. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0029052 | - |
dc.relation.ispartof | PLoS One, 2011, vol. 6, num. 12, p. 1e29052 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0029052 | - |
dc.rights | cc-by (c) Vinaixa, Maria et al., 2011 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) | - |
dc.subject.classification | Metabòlits | - |
dc.subject.classification | Malalties de l'ovari | - |
dc.subject.other | Metabolites | - |
dc.subject.other | Ovary diseases | - |
dc.title | Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 624708 | - |
dc.date.updated | 2018-06-08T10:11:18Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 22194988 | - |
Appears in Collections: | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
624708.pdf | 750.75 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License